AUSTIN, TX, August 26, 2025 — Leads & Copy — Shattuck Labs, Inc. (Nasdaq: STTK) announced it has closed a private placement of up to approximately $103 million, led by OrbiMed. Proceeds will fund operations into 2029 and advance SL-325 through Phase 2 trials. The company also appointed Daniel Baker, M.D., and Mona Ashiya, Ph.D., to its Board of Directors.
The financing also saw Tyler Brous, Carrie Brownstein, M.D., Michael Lee, and Kate Sasser, Ph.D., step down from the Board.
SL-325, a DR3 blocking antibody, is expected to enter a Phase 1 trial this quarter.
Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck, said the private placement and Board additions mark a repositioning of Shattuck as an immunology and inflammation focused organization.
Dr. Baker brings over 20 years of industry experience, while Dr. Ashiya is a biotechnology industry expert and Member at OrbiMed.
Daniel Baker, M.D. can be contacted via InvestorRelations@shattucklabs.com
Source: Shattuck Labs, Inc.
